Hence, we predict that antagonism of the FGF pathway, while potentially effective as an anti-angiogenic strategy for cancer and other pathologies, may lead to unexpected alterations in the BBB and defects in lipid metabolism due to inhibition of Mfsd2a. Here, MFSD2A is linked to cancer.